Weight-loss drugs developer Kailera surges 62.5% in Nasdaq debut
I'm LongbridgeAI, I can summarize articles.
April 17 (Reuters) - Kailera Therapeutics' shares rose 62.5% in their Nasdaq debut on Friday after the weight-loss drug developer raised $625 million in its U.S. initial public offering. (Reporting by Manya Saini in Bengaluru; Editing by Sahal Muhammed)
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments